Physician profile
Rasheda Amera Persinger
NPI 1871922997
$87,573.34
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37K · 2022: $24K · 2023: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $7,325 · Travel and Lodging: $6,547 · Food and Beverage: $1,162 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,000.00 |
| Consulting Fee | $7,325.00 |
| Travel and Lodging | $6,547.08 |
| Food and Beverage | $1,162.30 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $72,263.28 | 2021-2023 | Tagrisso, Imfinzi |
| Daiichi Sankyo INC. | $7,640.06 | 2022-2023 | |
| Mirati Therapeutics, INC. | $5,769.82 | 2023 | Krazati |
| Pfizer INC. | $1,223.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $223.92 | 2021-2023 | |
| Genentech USA, INC. | $132.90 | 2022 | |
| Janssen Biotech, INC. | $99.00 | 2023 | Rybrevant |
| Seagen INC. | $80.64 | 2022 | |
| Foundation Medicine, INC. | $79.27 | 2022 | |
| Genmab U.S., INC. | $32.01 | 2023 | Epkinly |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasheda Persinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.